ARQT arcutis.com: Return on Sales by Net Profit

Graphic logo of Arcutis (ARQT)

The Arcutis Biotherapeutics (ARQT) business relies on demand from dermatologists and patients with chronic dermatoses. The integral net margin indicator on GURU.Markets captures profitability dynamics, where 5.90 represents the latest metric reading. Sales of the drug Zoryve and new medical indications are driving revenue growth. Patent protection and the absence of steroid-related risks in the product compositions provide a competitive advantage.

Arcutis Biotherapeutics (ARQT) - Company Sales Margin from 07/04/2022 to 11/20/2026

Arcutis Biotherapeutics Inc (ARQT) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Fundamental valuation:Arcutis - ARQT
Finished products of Arcutis

Arcutis Biotherapeutics (ARQT), as a leader in developing safe non-steroidal treatments for psoriasis, demonstrates its efficiency through the share of net profit in total revenue. By analyzing relative net profit from sales on GURU.Markets, an investor assesses the business's ability to convert market confidence into real capital, tracking the impact of operating expenses on the company's final profitability.